Search
Fenoprofen Action Pathway
smpdb.ca/view/SMP0000696Drug actionDecreased prostaglandin synthesis in many animal model's cell is caused by presence of Fenoprofen. … Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway.
Enzymes: Prostaglandin E synthasePhenylbutazone Action Pathway
smpdb.ca/view/SMP0000701Drug actionIt can be used to treat the pain and fever in animal. However, Phenylbutazone is not approved in United State and United Kingdom for human use anymore because of severe adverse effects. … Decreased prostaglandin synthesis in many animal model's cell is caused by presence of phenylbutazone.
Drugs: Glutamic acid · Glutathione · Phenylbutazone · Dinoprostone · Calcium · Magnesium cation +5 moreEnzymes: Prostaglandin E synthaseTolmetin Action Pathway
smpdb.ca/view/SMP0000704Drug actionDecreased prostaglandin synthesis in many animal model's cell is caused by presence of tolmetin. … Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway.
Enzymes: Prostaglandin E synthaseTiaprofenic Acid Action Pathway
smpdb.ca/view/SMP0000705Drug actionDecreased prostaglandin synthesis in many animal model's cell is caused by presence of tiaprofenic. … Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway.
Enzymes: Prostaglandin E synthaseSalsalate Action Pathway
smpdb.ca/view/SMP0000707Drug actionDecreased prostaglandin synthesis in many animal model's cell is caused by presence of salsalate. … Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway.
Enzymes: Prostaglandin E synthaseSalicylate-Sodium Action Pathway
smpdb.ca/view/SMP0000708Drug actionDecreased prostaglandin synthesis in many animal model's cell is caused by presence of salicylate-sodium. … Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway.
Drugs: Glutamic acid · Glutathione · Dinoprostone · Calcium · Magnesium cation · Salicylic acid +5 moreEnzymes: Prostaglandin E synthaseCyclothiazide
go.drugbank.com/drugs/DB00606ApprovedAs a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. … The antihypertensive mechanism of cyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance
Categories: Heterocyclic Compounds, 2-RingSynonyms: 6-chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide, 6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxideMacimorelin
go.drugbank.com/drugs/DB13074ApprovedGrowth hormone (GH) is classically linked with linear growth during childhood. … In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability [A31481].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTechnetium Tc-99m sulfur colloid
go.drugbank.com/drugs/DB09397ApprovedTechnetium 99m sulfur colloid is a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging … This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.
Categories: Compounds used in a research, industrial, or household settingEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: PADCEV 20 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ , 1 ADET, PADCEV 30 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ , 1 ADET